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ABSTRACT 
Growth rates of pulmonary metastases in thirty patient 
with malignant melanoma were characterized by calculating 
Gompertz growth constants and tumor doubling time. No 
correlation between growth parameters, tumor doubling time, 
presence of tumor regression, extent of parenchymal involve 
ment at time of diagnosis, or response to chemotherapy as 
indicated by radiographic appearance was found. Possible 
explanations for these findings are discussed. The use of 
the Gompertz growth curve and the exponential growth curve 
to describe tumor behavior is studied and discussed. 

INTRODUCTION 
Malignant melanoma is a relatively uncommon disease, 
but its incidence v/orldwide is increasing. For 1983, there 
will be an estimated 17,400 new cases in the United States, 
about 2% of the estimated 855,000 new cases of noncutaneous 
cancer expected. There will also be 5,200 deaths due to this 
disease.^ Despite the rarity of melanomas, two to fifteen 
percent of all cases of pulmonary metastasis are due to this 
, 17, 32, 37, 72 
neoplasm. 
Nearly all patients with disseminated melanoma will have 
pulmonary involvement and in some reports the major cause of 
death has been respiratory failure, presumably due to paren- 
18 
chymal metastases. The chest radiograph often provides the 
29, 76 
first sign of disseminated disease and periodic x-rays are 
often an important part of the follow-up in patients judged 
to be at high risk for metastases. The chest x-ray is also 
used as an objective measure of a patient's response to 
chemotherapy once pulmonary metastases are diagnosed. 
This study was undertaken to investigate the relation¬ 
ship between growth rate and patient survival after the 
diagnosis of pulmonary metastases. The significance of tumor 
regression and response to chemotherapy will be examined. 
In addition some aspects of the Gompertz growth curve and the 
exponential growth curve will be compared. 
-1- 
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PATTERNS OF METASTASIS 
Malignant melanoma may metastasize to all organs of the 
human body and it is almost impossible to predict which organ 
system will be invaded from a given primary site. Multiple 
organ involvement is common in advanced melanoma. Patel et 
55 
al. reported that only 1-4% of their cases had single organ 
metastases at the time of death. Tables 1-4 summarize the 
findings of several investigators. 
29 
Gromet et al. published a prospective study of 324 pa¬ 
tients with malignant melanoma over a twenty-four month 
period. Thirteen of the 324 patients experienced dissemina¬ 
tion and of these the thorax was the initial site of metastasis 
76 
in twelve (92%). Webb and Gamsu retrospectively evaluated 65 
patients with thoracic metastases. Chest radiographs revealed 
abnormalities in 63 of the 65 patients and in 42 patients the 
chest film provided the first objective evidence of metastases 
beyond regional lymph nodes. Table 5 compares the radio- 
9 
graphic findings of Webb and Gamsu and of Chen et al. 
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MATERIALS AND METHODS 
Patients for this study were obtained from two sources. 
The Melanoma Clinic at Yale-New Haven Hospital provided a pop¬ 
ulation of fifty patients with known thoracic metastases seen 
since 1980. In addition, the Connecticut Tumor Registry pro¬ 
vided data on all patients who had been diagnosed as having 
malignant melanoma in Connecticut from 1970 through 1982, a 
total of 502 cases. There was considerable overlap in the 
two sources except for patients seen in the Melanoma Clinic 
who did not have their melanoma diagnosed in Connecticut and 
for patients who were diagnosed prior to 1970. 
From this population a total of 30 patients were found 
who fulfilled the following criteria: 
1. Histologically proven malignant melanoma 
2. Serial chest films of adequate technical quality 
which demonstrated pulmonary metastases. 
3. Adequate medical records to allow accurate dating 
of diagnosis of metastasis and subsequent follow¬ 
up. 
Only upright PA chest films were used; x-rays which em¬ 
ployed other techniques, e.g. portable or supine films, were 
not included. Films with marked differences in rotation or 
inspiratory effort were also excluded. Single and multiple 
parenchymal nodules were the objects of major interest. 
Those roentgenograms with only extra-parenchymal evidence of 
metastases were excluded as well as those which demonstrated 
the "mili ary" or "snowstorm" pattern of metastases. Films 
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in which nodules were obscured (by pleural effusion, for 
example) were also not used. 
Individual pulmonary nodules were measured using calipers 
and a centimeter rule. Measurements to the nearest milli¬ 
meter were taken along the axes of greatest and least dia¬ 
meter unless the lesion was circular, in which case only one 
measurement was made. Lesions in which the borders were 
subjectively judged to be too indistinct for accurate men¬ 
suration were omitted. Measurements from the chest films of 
a given patient were taken by the same viewer so that inter¬ 
observer variation would not be introduced. Intra-observer 
variation cannot be eliminated. This variation was not cal¬ 
culated although an attempt was made to estimate the error 
inherent in the measurement process (see results). Clear 
overlays or masks made by developing unexposed radiographic 
film were used as an aid in identifying and following the 
nodules. The mask was placed over an x-ray and the nodules 
outlined and identified. The mask made it easier to identify 
each nodule for measurement, to judge if there had been any 
gross change in the size of the lesions, and to more readily 
determine if a nodule had been seen previously or was a new 
metastases. 
The films of thirty patients, sixteen males and fourteen 
females, were studied. There were twenty-nine whites and one 
black. Average age at time of initial diagnosis was 49.3 
years for all patients, 53.2 for males and 44.8 for females. 
The ages ranged from 19 years to 69 years. Average age at 
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diagnosis of pulmonary metastases was 51.9 years overall, 55 
years for males and 48.4 years for females, with an age range 
of 24 to 70 years. At time of diagnosis eighteen patients 
were in clinical Stage I, five in Stage II, six in Stage IV 
and one was unspecified. 
Of the thirty patients in the study, nine were alive 
according to the most recently available medical records. 
The rest had succumbed with evidence of active disease at 
death. The mean survival time of the twenty-one deceased 
patients was 9.8 months from diagnosis of pulmonary metas¬ 
tases. Table provides further information on each patient. 
The time encompassed by the series of chest films used 
to evaluate pulmonary metastases in these patients ranged 
from 25 days to 1251 days, with a mean of 260 days. 
Growth parameters were calculated from the acquired 
data by applying the equations of the following section. 
Patients were separated into prognostic categories and Kaplan- 
34 
Meier estimates of survivorship were determined for each 
category and then compared by use of the log-rank test.~^ 
Survival time in each patient was defined as the period from 
diagnosis of pulmonary metastases to death or to end of 
observation. 
Multiple nodules were treated as the summation of inde¬ 
pendently behaving single nodules. The value of doubling 
time or of the Gompertz growth parameters attributed to a 
patient was, unless otherwise indicated, the mean of those 
parameters as calculated for each individual nodule. 
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MATHEMATICS USED IN GROWTH ANALYSIS 
The mathematical characterization of the growth of tumors 
has interested investigators for many years. In 1956, Collins 
12 
et al., presented a graphical method for the estimation of 
tumor doubling time which was based on the hypothesis that 
the simplest view of malignant cell growth was to assume that 
each cell divided into two cells at a constant rate, i.e., 
one cell became two, each of the resulting two divided so 
that there were now four cells, then eight, then sixteen, 
etc. This would result in the growth curve seen in Figure 1. 
From the measured diameter of a nodule at two different times 
the doubling time could be calculated (Figure 3) with the aid 
of semilogarithmic graph paper. 
6 3 
Subsequently, Schwartz derived an approximation formula 
for doubling time which could be substituted for graphical 
methods on semilog paper. The equation was: 
(1) 
t = _1_ 
u 10 log (Dt/DQ) 
where t = doubling time 
t = time interval between first and second measurements 
= diameter at second measurement 
D = diameter at first measurement, 
o 
As data of the actual growth patterns observed in tumors 
accumulated, the validity of the assumption of exponential 
39 
growth at a constant rate was questioned. Laird, after sur¬ 
veying the available literature, pointed out that exponential 
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growth of tumors had been observed only rarely and then for 
only brief periods. When most tumors are observed over a 
sufficiently extensive range of growth, they are found to 
expand at a progressively slower rate as the tumor enlarges 
with no appreciable period of growth at a constant rate as 
sould be expected for simple exponential growth. In most 
cases, tumor growth is smoothly curvilinear on a semi-log 
plot throughout growth. This implies that the specific growth 
rate of tumors is usually not constant even for a short 
period of time, but decreases steadily. 
This pattern of growth has been found in many biological 
systems in addition to malignancies and is expressed by the 
Gompertz function: 
£(l-e~at) (2) 
a 
S (t) - S (0) e 
where S(t) = tumor size at time t (size may be defined as 
weight, volume, or number of cells) 
S(0) = initial tumor size 
are constants. 
. . — c*t 
If m equation 2, e is expressed as a power series in ctt, 
then for the case where ext is small, the growth function re¬ 
duces to: (3) 
S(t)/S(o) = e^ 
that is, the growth function describes simple exponential 
growth. 
It is also evident from equation 2 that as the value of 
becomes large, the Gompertz function approaches a horizontal 
asymptote whose value is defined by 
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where 
Q/n 
SM /S(o) = e /a 
Max 
S,„ = theoretical upper limit of tumor size. 
Max 
If equation 4 is substituted into equation 1, the result 
is : 
S (t) S.. e 
Max 
-<xt (5) 
or 
S(t)/SM = e Max 
-£e 
Ov 
-ext 
£P 
SM /S(t) = e Max 
c* 
(6) 
(7) 
In (SM /S (t) ) = & e -<*t (8) 
In In (sMax/S (t) ) = In J- - ext (9) 
Thus growth can be depicted rectilinearly with slope of 
if In In [S., /S(t)] is plotted as a function of time. 
Spang-Thomsen et al, further transformed equation 9 by 
showing experimentally that the measurements of the three 
diameters of a tumor are in proportion during growth, and as 
d^(t) = d2(t) on average 
(10) 
d^ (t) = kd^(t) = kd2(t). 
If two-dimensional tumor size, A(t), and volume V(t), are 
given respectively by (11) 
A(t) = d1(t) d2(t) 
4 7f dl(t> d2(t) 
3 
d^ (t) 
V(t) 2 2 2 
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then 
V (t) = if if 
(12) 
= ^ k A (t) 
3/2 
Since the square of V(t) is proportional to the cube of A(t), 
equations 1 and 9 can be transformed to 
-ext (13) 
-&LM - 
A (t) = A (o) e ex 
(1 e ) 
In In (A.. /A (t) ) = In — - t 
Max 
14) 
where A /3 
& 
ert 
(15) 
and AMax = A(o) e " (16) 
The value of may be calculated if the two-dimensional 
tumor size is known at two different points in time by 
utilizing equation 14. For example, if the tumor was measured 
at times t^ and t2 with resulting values of A(t^) and A(t2) 
respectively, then 
(17) 
A. 
In In Max 
A (t x) 
In In 
AMax 
A(t2) 
(t2 t1). 
One difficulty with using the various forms of the Gom- 
pertz function is that the values of S(0), , A(0), A„ , 
^ Max Max 
J0 
^ or of are not known. There are several methods by 
which estimates of these values may be obtained but the one 
40 
used by Lloyd is perhaps the simplest. An initial estimate 
of A,, is made and then the observed values of A(t) are 
Max 
plotted using equation 14. If the estimate of A Max is high. 
the plotted points will be displaced upwards from a straight 
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line at larger values of t. Conversely, if the estimate is 
low, the points will exhibit a downward curvature. Spang- 
Thomsen et al., used the method of Lloyd to determine values 
of A for three human malignant tumors, including a malig¬ 
nant melanoma, transplanted to nude mice. The estimates of 
In A.. ranged from 6.2 to 8.5 with a mean value of 7 corres- 
2 ponding to maximum two-dimensional tumor sizes of 492 mm to 
2 2 4915 mm with a mean of 1097 mm . The deviation from linear¬ 
ity of equation 14 was found to be quite small for a wide 
range of values of In . It then becomes convenient to 
choose a common maximum size in order to place the variation 
of growth into the single parameter OC . While wide variations 
of In A does not significantly affect the linearity of 
equation it should be remembered that the estimation of o< is 
closely correlated with the estimation of In A,, so that 
Max 
growth parameters cannot be compared unless the same value of 
In is used in all calculations. 
The Gompertz function is not usually considered in terms 
of doublings and of doubling times and the relationship of 
the Gompertz constants (b and o to the doubling process is 
not readily evident. Such a relationship has been derived 
39, 41 
by several authors and is given below. 
t = — In [ (3 
c* cx (/3/c* In(S/S 
(18) 
with 
o 
= S(t) 
= S(O) 
for the sake of simplicity in the notation. The doubling time 
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is expressed as: 
, 1, , , c*ln2 
tn =-In ( 1 - 'is— e 
D ex p 
a t 
)> 0 
Substituting equation 18 into equation 19 
1., r , In 2_ 
D a nL p/c* - ln(S/SQ) 
or, equivalently 
tn = - iln[ 1 
D c* 
In 2 
In (S.. /S) 
Max 
In terms of A(t) 
t = - - In [ 1 
D oc 
21n2 
3 In (A.. /A) 
Max7 
(19) 
(20) 
(21) 
(22) 
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RESULTS 
I. Estimation of 
The modification of Spang-Thomsen on the method of Lloyd 
was used to obtain estimates of Identical observed 
values of A(t) were plotted using equation 14 with each of 
the estimates of A^^ Linearity of the transformed growth 
function was checked by calculating correlation coefficients 
of the individual regression lines. The smallest value of In 
‘A'Max compatible with the observed data was 8, thus the various 
estimates of In A., were set at 8, 8.5, 9, and 10. The 
Max 
correlation coefficient obtained with each value of In A*, 
Max 
was greater than -0.95 although the slope of the line of best 
fit (equal to - cx) varied from-0.0032 with In A^ = 8 to 
-0.0022 with In A,. = 10. This demonstrates that wide 
variations in the value of In A.. have little effect on the 
Max 
linearity of the growth function but that the estimation of c* 
is closely tied to the estimation of In AMax. Figure 5 shows 
the growth curves obtained using the various estimates of AM_^. 
II. Estimation of Measurement Error 
An attempt was made to estimate the magnitude of the 
error to be expected from the measurement of pulmonary nodules 
5 
from radiographic films. Brenner et al., found that by re¬ 
measuring the same shadow and comparing similar radiographs 
of the same neoplasm taken within a short period of time 
there may be an error of 20-30% in the volume or 7-10% in 
the diameter of the tumor. 
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Measurements of pulmonary nodules from a series of 
radiographs from two patients, each with multiple lesions, 
were made by the same observer on two separate occasions 
several months apart. The mean absolute difference between 
each of sixty-eight corresponding measurements was 1.3 mm 
with a standard deviation of 1.1 mm. Since measurements 
were made to the nearest millimeter, only a change greater 
than or equal to two millimeters in the size of the nodule 
was considered significant. While this condition was applied 
to all measurements, it has a much greater influence in the 
calculations based on the smaller nodules where even a 1 mm 
change would have significant effect on the computed volume 
and the two-dimensional tumor size. 
III. Calculation of Gompertz Constant 
For In equal to 8, the mean value of C* for all 
measured lesions was 0.0044 with a standard deviation of 
0.0034. The value of c* ranged from -0.00042 (indicating 
contraction of the lesion) to 0.019. For each nodule, O, was 
computed by using measurements from the first and the last 
films in which the lesion was noted and the applying equation 
17 with A.. =. e^ = 2981 mm^. 
Max 
The patients were separated into two prognostic cate¬ 
gories. The first comprised those patients in whom the mean 
value of cx was greater than one standard deviation below the 
sample mean, i.e., less than 0.001, while the second con¬ 
tained the remaining patients. The composition of the two 
groups is given in Table 6. Survivorship for both groups was 
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estimated using the Kaplan-Meier method and survival curves 
(Figure 6) were obtained by plotting the cumulative propor¬ 
tion surviving, P(t), versus time. The two survival dis¬ 
tributions were then compared by the log-rank test. No 
significant difference between the survival distributions 
was detected. 
2 
For In A., equal to 8.5 (A.. = 4915 mm ) the mean 
Max ^ Max 
value of for all lesions was 0.0033 with a standard de¬ 
viation of 0.0023. The range of values was from -0.00027 to 
0.01. Patients were again separated into prognostic cate¬ 
gories according to the criteria used previously, i.e., 
patients in whom the mean value of c* was less than the sample 
mean minus the standard deviation. Since that cut-off was 
again 0.001 the composition of each group was identical to 
those obtained using the value of eight for In A^ . 
It may be helpful to translate the above variations of o( 
into more familiar terms. From equation 5 
_J?e" Wt 
S(t) = SM e - '5> 
Max 
The values of S(t) after an arbitrary period, e.g., 100 days, 
may be calculated for cx( =0.001 and 0(^=0.0044 (derived when 
In A,, = 8). If a common maximum size and a common initial 
Max 
size are selected for both values of ^ , then the ratio ( (3/cx ) 
remains constant for both cx . (Equation 4). Thus: 
ft ft 
= k 
cx cx 
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and 
a, t 
-ke 
S1(t) S e 
-ke 
S2(t) S e 
e 
e 
-0.44, 
ogt 
= e 
-0.26k 
e 
(23) 
If the maximum size were 1000 times the initial size5k would 
equal In 1000, or 
Sl(t) 
S2(t) 
-0.26 In 1000 
e 
0.166 
After 100 days, a tumor characterized by c*, = 0.001 would have 
only 16.6% of the volume of a tumor characterized by =0.0044. 
IV. Comparison Using Tumor Doubling Time 
Doubling times were calculated using the approximation 
formula given by Schwartz to determine if results differed 
significantly when assuming an exponential growth curve 
rather than a Gompertz growth curve. The mean doubling time 
was 58.6 days with a standard deviation of 39.9 days. 
Patients with doubling times greater than 100 days were com¬ 
pared to those with doubling times of less than 100 days. 
Composition of the groups is given in Table 7. No signi¬ 
ficant difference could be detected in the two groups. 
(Figure 7). 

-16- 
56 
Plesnicar, et al., obtained a mean doubling time of 49.1 
days in patients receiving no anti-cancer therapy. It was 
also noted that the mean doubling time for nodules 3.0 mm to 
14.9 mm in diameter was 24.9 days while the mean doubling time 
of nodules 15.0 mm to 59.9 mm in diameter was 51.0 days. The 
observed dependence of the growth rate on tumor size is not 
accounted for simple exponential growth is assumed. Equation 
22 will allow a determination of the variation in doubling 
time expected when a Gompertz growth curve is assume. Accord¬ 
ing to the data presented by Plesnicar, et al., the mean 
diameter of lesions in the size range of 3.0 mm to 14.9 mm 
was approximately 8 mm and the mean diameter of the group 
ranging in size from 15.0 mm to 59.9 mm was approximately 
26 mm. The ratio of the doubling time of the larger nodule 
versus the doubling time for the smaller nodule was calcu¬ 
lated for values of A.. of 2981 mm^, 4915 mm^, and 8103 mm^ 
(corresponding to In A^ equal to 8, 8.5, and 9). The 
resulting ratios were 2.9, 2.35, and 2.05 which compare 
favorably with the observed ratio of 2.05 (51.0/24.9). 
V. Comparison Using Tumor Regression 
A decrease in tumor size of greater than fifty percent 
is often taken to indicate favorable response to therapy. 
Total estimated tumor volume at the time of each chest radio¬ 
graph was determined for all thirty patients. The patients 
were categorized on the basis of whether a fifty percent or 
greater decrease in tumor volume had occurred sometime during 
the period of observation (Table 8). Volume was calculated 
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using each of the two diameters measured on the frontal film 
with the third diameter taken to be the average of the first 
two. It should be noted that no patients had complete re¬ 
mission, i.e., 100% regression of tumor. 
One-third of the patients demonstrated a greater than 
fifty percent regression of the volume of their pulmonary 
lesions, a proportion comparable to that seen at other medi- 
9 
cal centers. However, no significant difference in survival 
was detected between those who did and those who did not 
display tumor volume decrease. 
Patients were then categorized according to whether the 
total calculated tumor volume continuously increased through 
the observation period or whether the volume both increased 
and decreased during the interval (Table 9). No significant 
difference between the survival distributions was observed 
(Table 9). This is in agreement with the findings of Webb 
and Gamsu. 
VI. Homogeneous vs. Mixed Growth Patterns 
It is a common observation that in some patients all 
pulmonary metastases will display continuous growth while in 
other patients there may co-exist populations of both growing 
and shrinking lesions. Patients were separated into these 
categories (Table 10), and the survival curves plotted 
(Figure 10). No evidence of a significant difference between 
the two survival distributions was found. 
VII. Significance of Tumor Volume at the Time of Diagnosis 
The extent of parenchymal involvement at the time of 
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diagnosis of pulmonary metastases varied widely from patient 
to patient. Since survival was defined as starting at the 
time of diagnosis of metastases, it was important to deter¬ 
mine if the extent of disease at diagnosis was correlated to 
subsequent survival. The initial volume of the metastases 
were used to separate the patients into three groups. The 
3 
first contained those m whom volume was less than 525 mm , 
the second those in whom volume was between 525 mm^ and 
3 
2600 mm , and the third contained those with initial volumes 
3 
greater than 2600 mm (Table 11). No statistical difference 
in survival between any of the groups was found. 
VIII. Comparison Using Response to Chemotherapy 
It would seem reasonable to assume that patients who 
manifested a positive therapeutic response would do better 
than those patients who did not respond. For this analysis 
it was necessary to know the type and duration of chemotherapy 
given to the patient and to have at least two chest radio¬ 
graphs within the period of each anticancer regimen. Ten 
patients met these conditions. 
Positive response to chemotherapy was defined as at 
least a twenty-five percent decline in the value of c* or cX 
less than zero during a given therapeutic regimen as compared 
to the preceding interval. Responders included those patients 
who demonstrated a positive chemotherapeutic effect as defined 
above upon the first use of chemotherapy and those who had a 
positive response after a change in the regimen. Non-respond¬ 
ers included those patients in whom the values of cX remained 
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constant or increased during therapy, and those who developed 
new metastases while on chemotherapy. No difference between 
the two survival curves was noted. 

20- 
DISCUSSION 
This study was unsuccessful in finding any correlation 
between the rate of growth of pulmonary metastases and sur¬ 
vival time after diagnosis of metastases in 30 patients with 
malignant melanoma. The question which now poses itself is 
whether there is a correlation which has not been detected, 
whether there is absolutely no useful correlation between 
growth rates and prognosis, whether a correlation may exist 
but only under specific conditions not recognized in this 
analysis, or whether there are other explanations. One may 
ask even more basic questions about the validity of assuming 
logarithmic or Gompertzian behavior in the growth of metastases 
in vivo. 
The first possibility is that a valid correlation exists 
between the growth of metastatic lesions and prognosis but 
that this was not recognized due to limitations of the pro¬ 
tocol used. Not the least of the limitations is the small 
size of the sample involved. Such a small number of patients 
increases the likelihood of an erroneous result due to the 
effects of a biased sample. The sample, however, does not 
seem to be terribly unrepresentative of the population of 
melanoma patients as a whole except for the fact that by 
definition they all have disseminated disease. The male: 
female ratio was 16:14, average age at initial diagnosis was 
years and average age at diagnosis of pulmonary meta¬ 
stases was 51.9 years. The subdivision of patients into 
the various categories defined by the study did not seem to 
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cause a sample bias which would adversely affect detection of 
an increased survival trend. Indeed, in some cases it appear¬ 
ed that the subgroup associated with the slower growth rates, 
and presumably better survival, would a priori be expected to 
do better due to a greater proportion of females (the majority 
pre-menopausal) and a lower mean age than the subgroup with 
more rapidly growing metastases. While it may be that this 
tendency of a group of patients with characteristics asso¬ 
ciated with a better prognosis to manifest a slower growth 
rate is significant, it did not translate into improved 
survival. It is also possible that the observation periods 
or distribution of chest x-rays was not optimal for accurate 
determination of growth parameters. The mean time of ob¬ 
servation (defined as time between first and last chest 
films used in measurements) was 236 days but this ranged from 
25 to 1251 days. The accuracy of the calculation of growth 
parameters increases as the relative ratio of the observation 
period to the tumor doubling time but the prognosis of pa¬ 
tients with disseminated melanoma is generally so poor that 
the observation period is not much greater than the doubling 
time. In this instance, one could compare the mean doubling 
time for all measured lesions (60 days) to the mean time of 
observation (236 days) and see that, on average, only two 
doublings are seen per patient. It should be noted that the 
period of 236 days should not be taken to also be the mean 
survival time after metastases. The distribution of the chest 
4 
x-rays in the observation period may also affect accuracy, 
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but this is less likely to be the major cause of error. 
The second possibility is that there is no significant 
correlation between growth rate and prognosis. This is the 
conclusion reached by Webb and Gamsu in their study of 
thoracic metastases in malignant melanoma. Other experi¬ 
mental evidence, however, suggests that a positive correla- 
73 
tion may exist. Zanker et al., determined that appearance 
of subcutaneous and pulmonary metastases in one patient was 
21, 20 
associated with decreased cell generation time. Day et al., 
found that mitotic rate was an important prognostic variable 
2 
in truncal melanomas and that mitoses/mm was an important 
factor in lesions 1.51 to 3.99 mm thick, i.e., in those pa¬ 
tients where metastases is most likely to occur. While these 
findings are interesting, it must be emphasized that the 
relationship between growth rate and subsequent prognosis 
proposed by these studies is predicated on the idea that the 
growth rate can be used to assess the likelihood that 
metastases will occur. It is only by extension can the 
question be posed if the growth rate can also be used as a 
prognostic variable after dissemination. 
Another explanation for these results may be that the 
growth rate is only one of several factors determining prog¬ 
nosis in patients with pulmonary metastases. At the time of 
diagnosis of pulmonary metastases, twenty-six of thirty pa¬ 
tients in this study had documented evidence of other meta¬ 
stases and/or recurrences. This introduces a variable which 
is often difficult to assess and to quantify yet which may be 
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the limiting factor in a patient's survival. Clearly a pa¬ 
tient with simultaneous central nervous system and pulmonary 
metastases may die due to complications from the former even 
if the latter appears to have stabilized. Since it is the 
rule, rather than the exception, that multisystem metastases 
will occur, any use of the growth rate or its parameters will 
have to account for the influence of extrapulmonary metastases. 
One solution may be to separate the patients into cate¬ 
gories based on the sites of metastatic disease, e.g., 
pulmonary vs. pulmonary and central nervous system v.s 
pulmonary and gastro-intestinal, etc. While this may make it 
possible to determine a relationship between growth and sur¬ 
vival exists in the case of metastases only to the lung, it 
does have a number of difficulties. First and probably fore¬ 
most is that a study restricted only to patients with iso¬ 
lated pulmonary metastases and adequate medical and radio- 
graphic follow-up would likely have a very small sample size. 
Second, unless the patient comes to autopsy, there will be 
considerable uncertainty as to whether disseminated disease 
is restricted solely to the lungs throughout the period of 
observation as even the most thorough metastatic work-up is 
not foolproof and even the most enthusiastic researcher is 
unlikely to subject patients to periodic full-scale workups 
to ensure documentation of extent of disease in the event the 
patient's family refuses autopsy. Third, results of such a 
study may be of academic interest but due to the severe con¬ 
straints on the design, the results are unlikely to be easily 
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applicable to either medical or radiologic diagnosis and 
treatment. 
Alternately, one could develop prognostic models and 
analyse combinations of variables using multivariate an¬ 
alyses as has been done in the study of prognostic factors 
in Stage I melanoma. This approach is beyond the scope of 
this thesis. 
There are many other variables not accounted for in this 
61, 65 
analysis. Recent reports claim that cigarette smoking is a 
significant risk factor in developing metastases in melanoma, 
possibly due to a suppression or diminution of host response. 
If immunologic suppression is indeed responsible for the in¬ 
creased metastatic rate in smokers, then patients who con¬ 
tinued to smoke after the discovery of pulmonary metastases 
may also have a decreased survival time compared to non- 
smokers . 
In addition, no attempt was made to match patients in the 
prognostic categories defined by the calculated growth para¬ 
meters according to stage at initial diagnosis because it was 
assumed that the fact that all patients were now Stage IV 
obviated that need. However, if it is shown that stage at 
initial diagnosis also affects survival once dissemination 
has occurred, then this will have to be allowed for in sub¬ 
sequent analyses. 
There is also the problem of what is the optimal way to 
assess the behavior of multiple nodules. In the past, some 
71 
investigators have chosen to use only the fastest growing 
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nodule in their analysis on the grounds that it was expressing 
the most malignant behavior. This does not take into account 
the influence of local factors such as variation in blood 
supply or the fact that the growth rate is volume and time 
dependent, as observed by Plesnicar. Thus one can evaluate 
only a small lesion on the exponential portion of its growth 
curve while a much larger lesion in its plateau phase kills 
the patient through respiratory embarrassment and then erro¬ 
neously assert that a short doubling time is correlated with 
a poor prognosis. Even the use of the Gompertz constants to 
account for the volume and time dependence of the growth rate 
may not be a satisfactory solution. In the hypothetical ex¬ 
ample given previously the small lesion may have a more rapid 
intrinsic growth rate than the larger nodule yet may still 
not be the limiting factor in the patient's survival. This 
also demonstrates that the method used in this analysis, 
i.e., equal weight being given to all calculated parameters, 
may also be unsatisfactory. The problem is accentuated by 
the independent patterns of behavior expressed by the nodules. 
49 
Nathan found in his analysis of multiple nodules in a single 
patient that the doubling times determined were usually of 
the same order of magnitude. There was often a wide varia¬ 
tion in the growth parameters calculated for the different 
nodules and that at times there was even co-existence of 
expanding and contracting lesions. The significance of this 
pattern is unclear but there was no difference in survival 
between patients with this phenomena and those without. 
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There is also uncertainty over whether a given volume in¬ 
crease in one nodule is of the same importance as an equal 
volume gain spread over several nodules. The assumption 
used was that there was no difference but there is little or 
no evidence in the literature one way or the other. Webb 
and Gamsu found no difference in survival in patients with 
single versus multiple nodules. 
A related question is the significance of the appearance 
of a new nodule or the disappearance of an old nodule. The 
clinical scale used by many oncologists assigns the most dire 
rating to the situation in which the first nodule is seen but 
what of the appearance of subsequent nodules? What addi¬ 
tional weight, if any, should be given to the appearance of 
a new nodule other than to factor its contribution into the 
calculation of tumor volume and mean growth parameters? 
Since over two-thirds of the patients in this study demon¬ 
strated the appearance of new lesions sometime in the course 
of their disease, this is not an idle question. Most likely 
some satisfactory method of weighting the appearance of new 
nodules will have to be developed in order to bring the experi¬ 
mental growth model more in line with the clinical model. 
Ideologically it makes sense that new nodules are poor prog¬ 
nostic signs for the patient. The new lesions could repre¬ 
sent (a) continued metastases from another site, (b) re- 
78 
activation of dormant tumor cells, or (c) continued growth 
of a small inoculum of metastatic cells which was previously 
of insufficient size to be detected. If the patient were 
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receiving therapy any of the above possibilities would indi¬ 
cate a poor response to treatment. 
The disappearance of a nodule is also difficult to eval¬ 
uate as one often cannot be certain if a nodule has dis- 
74 
appeared due to therapy. Szamosi pointed out that the radio- 
logic appearance of any nodule can vary considerably from 
one film to another even to the point of approaching invisi¬ 
bility. 
Another result of the analysis of the lesions was that 
the extent of disease at the time of diagnosis of pulmonary 
metastases did not have a detectable effect on the subsequent 
survival. This was a pertinent question since it was possi¬ 
ble that patients diagnosed late in the course of their 
disease may have artificially low survival times simply be¬ 
cause they went unrecognized as having disseminated lesions 
much longer than others in the sample. This finding is quite 
surprising as one would expect that fewer and smaller lesions 
would be a better prognostic sign than more and larger 
lesions. If this finding is valid it would serve to further 
emphasize the idea that survival is not simply related to 
extent and rate of growth of disease but to many variables, 
e.g., metastases in other organ systems. 
Even more surprising and disturbing is that patients who 
had a greater than 50% reduction in calculated tumor volume 
sometime during the period of observation did no better than 
those who did not. This is in agreement with Webb and Gamsu's 
finding that regression is not a positive prognostic sign 
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(although they may not have used the greater than 50% re¬ 
duction as their criteria). Chen et al., found that 34% of 
the patients in their study had 50% or more tumor regression, 
which is almost identical to the 33% in this study. They do 
not comment on whether these patients had increased survival 
time but do note that in cases successfully treated by systemic 
chemotherapy, pulmonary nodules shrink much faster than lymph 
nodes (about 10% of cases). Adenopathy was not evaluated in 
this study because it was judged that the treatment with 
BCG given to many of the patients would make it difficult to 
distinguish nodal metastasis from BCG reactive nodal enlarge¬ 
ment. The patients in this study responded poorly to chemo¬ 
therapy. Several demonstrated measurable reduction in tumor 
size during treatment but tumor growth continued unabated 
after cessation of therapy. 
Several other observations can be made. The mean doubl¬ 
ing of all lesions as calculated by the Schwartz approxima¬ 
tion was on the order of sixty days. Plesnicar gave a figure 
of 49 days but his patients were on no systemic chemotherapy. 
Webb and Gamsu found a mean doubling time of two months in 
their patients, the majority of whom received therapy. 
Plesnicar also noted that doubling time for lesions measuring 
3 mm to 14.9 mm in diameter was 24.9 days while those meta- 
stases from 15.0 mm to 59.9 mm in size had a mean doubling 
time of 51.0 days. This variation in doubling time is not 
accounted for in models using the assumption of exponential 
growth but fits very well with the model using the Gompertz 
growth curve. The experimental data used in determination 
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of In AMax in this study also fit well with the Gompertz 
model with the correlation coefficient of the equation 
P, 
In In =--ext being greater than -0.95. 
A (t) o ^ ^ 
It is by now evident that the evaluation of pulmonary 
metastases is fraught with difficulty. If further studies 
are done to confirm or correct the findings presented here, 
some suggestions may prove useful. 
(a) It may prove easier if the study is a prospective one; 
prospective in the sense that the collection and organization 
of radiographic and medical data be done systematically with 
the study in mind. For example, a flow sheet could be kept 
giving the exact date of the initial diagnosis of pulmonary 
metastases, the exact dates and type of therapy, and the date 
of serial chest x-rays. Dating is especially important in a 
disease where progression can be rapid and survival time 
short. More accurate dating would allow expansion of the time 
scale to weeks, or even days and thus increase the possi¬ 
bility that differences in survival can be detected, although 
such a difference may not prove to be of major benefit to 
the patient. Many patients were excluded from all or several 
parts of the study because medical documentation, while more 
than adequate for patient care, was not accurate enough for 
analysis. 
(b) Once a patient has been found to have metastases he 
should be followed with serial x-rays at regular intervals of 
perhaps one month. This is generally done in any case to 
monitor the patient's disease. 
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(c) Future analysis may multivariate or covariate analysis 
to determine important prognostic parameters. 

Table 1 
Incidence of Metastatic Melanoma in Various Organs 
(Autopsy Series) 
>ystem Reference Das Gupta & 
Brasf ield^ 
4 
Einhorn et ai. 
6 
Patel et al. Meyer' | Natnanscn et 3l. 
Period 1935-60 1967-73 1959-74 1927-75 1547-66 
Institution Memorial M.D. Anderson Roswell Park Ponaville Harvard Hospitals 
Pt. No. 125 96 216 74 22 
lespiratory Lung 70% 87% 71% 76% 82% 
Pleura 24% 15% 
— — — 
Diaphragm 17% 15% 
— — — 
Upper tract 
— 
2% 8% 
— 
Sastrointestinal Liver 68% 76% 58% 54% 77% 
Peritoneum 13% 26% 43% 
— 
— 
Pancreas 53% 38% 38% 32% 41% 
Spleen 36% 43% 31% 27% 36% 
Small bowel 58% 26% 36% 34% 
Colon 22% 14% 28% 24% 
Stomach 26% 7% 23% 26% ► 36% 
Gall bladder 15% 4% 9% 20% 
Esophagus 4% 3% 9% — 
tone, soft tissue 
ymph node 
Breast 
Skin 
Subcutaneous/ 
muscle 
Vertebra 
Other bones 
Abdomen 
Thorax 
Others 
20% 
75% 
42% 
36% 
65% 
55% 
2% 
54% 
50% 
23% 
74% 
68% 
49% 
56% 
55% 
42% 
7% 
35% 
63% 
41 ‘ 
72% 
:ns Brain 39% 54% 49% 40% 36% 
Cardiovascular Heart 
Pericardium 
49% 
10% 
55% 
11% 
47% 
24% 
40% 41% 
Endocrine 
Jrinary 
lanital 
Adrenals 
Thyroid 
Pituitary 
Parathyroid 
Kidney 
Bladder 
Ureter 
Prostate 
Testis 
50% 
39% 
5% 
2% 
54% 
21% 
45% 
18% 
3% 
58% 
14% 
2% 
5% 
8% 7% 
47% 
26% 
16% 
35% 
13% 
51% 
23% 
2% 
38% 
16% 
3% 
7% 
12% 
36% 
27% 
45% 
14% 
14% 

Table 2 
Common Sites of Metastatic Melanoma 
Overall versus Initial Involvement 
Reference 
Patel et al. 
(1978) 
Das Gupta & 
Brasfield (1964)3 
9 
Stehlin et al. 
(1967) 
4 
Einhorn et al 
(1974) 
Pt. No. 216 216 652 222 332* 
Organs 
involved 
Overall involvement 
at autopsy 
Only site involved 
at autopsy 
First site of 
extra-regional 
metastasis 
Initial site 
of distant 
metastasis 
Initial site(s) 
of distant 
metastasis 
.ung 71% 2% 7% 21% 45% 
.iver 58% 1% 4% 4% 13% 
.ymph nodes 74% 2% 
- 
19% 29% 
train & meninges 55% 4% 6% 8% 12% 
Sone 49% 0 2% 5% 8% 
jastrointestinai 43% 0 2% — 2% 
ratients were referred for chemotherapy of disseminated non-ocular melanoma. In many patients, more than one organ was involved. 
Table 3 Table U 
Less Freauent Sites Causes of Death 
of Melanoma .Metastasis 
Percent of Percent 
Site Patients Cause of 216 patients* 
Scalp'' 8 Respiratory failure 39 
Dura'' 5 CNS complication 20 
F.yo3 1 
Cardiac failure 10 
3 
Bilo duct 6 
Liver failure 7 
Infection 7 
Duodenum'' 12 
Renal failure 2 
Rectum 5 
Adrenal failure 1 
Anus'* 1 
Miscellaneous 14 
.. 3 Uterine cervix 2 
3 
Broad ligament 1 
•Patients were autopsied from 1959 to 
1U74 (Patel et al.6). 
Labia3 1 
Bone marrow^ 16 
Vagina^ 2 
0 
Major blood vessel 6 

Table 5 
Normal chest x-rav film 2 
Pulmonary metastasis 57 
Solitary nodules 14 
Multiple nodules 41 
Miliary (snowstorm) nodules g 
Lymphangitic spread 5 
Enlargement of lymph nodes 28 
Pleural effusion , - ^ jq 
- Atelectasis and bronchial obstruction 8 
Lytic bone metastasis 6 
Cardiomegaly _ — - -,4 
7^ 
From Webb and Gansu 
Lesion No Patients (%) Average Survival (Months) 
Adenopathy . 
Pulmonary metastasis: 
9 (7) 10.3 
Multiple nodules 52 (40) 30.9 
Solitary nodules 26 (20) 50.7 
Miliary intiltrate 2 (1.5) 4 
Pleural effusion 3 (2) 23 
Extrapleural mass 1 (0.8) 25 
Bone lesion 1 (0.8) 8 
Combined 36 (28) 20.5 
9 
From Chen, et al. 
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Table 6 - Composition of categories with In A =8, 8.5. Max 
<0.001 > 0.001 
No. of Patients 7 
Male:Female 2:5 
Mean age at Dx. 44.7 yrs. 
of mets 
23 
14 : 9 
54.1 yrs. 
Table 7 - Composition of categories using doubling time. 
t_ > 100 days 
lJ 
t < 100 days 
No. of Patients 9 
Male:Female 4:5 
Mean age at Dx. 47.4 yrs. 
of mets 
21 
9:12 
53.8 yrs. 
Table 8 - Composition of categories using > 50% regression 
>50% regression <50% regression 
No. of Patients 10 
Male:Female 5:5 
Mean age at Dx. 46.8 yrs. 
of mets 
20 
11:9 
54.5 yrs. 
Table 9 - Continuous Growth vs. Growth and Regression. 
Continuous 
Growth 
Growth and 
Regression 
No. of Patients 17 
Male:Female 9:8 
Mean age at Dx. 53.2 yrs. 
of mets 
13 
7:6 
50.2 yrs. 
Table 10 - Homogeneous (all growing) vs. Mixed (growing 
and shrinking). 
Homogeneous Mixed 
No. of Patients 17 
Male:Female 9:8 
Mean age at Dx. 53.9 yrs, 
of mets 
13 
8:5 
, 50.2 yrs. 
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Table 11 - Initial Tumor Volume. 
V< 525 mm' 525<V< 2600 mm' 
No. of Patients 
Male:Female 
Mean age at Dx. 
of mets 
12 
5:7 
50.7 yrs. 
7 
4:3 
48.6 yrs. 
V > 2 6 0 0 
11 
7:9 
55.4 
Table 12 - Response to Chemotherapy. 
No. of Patients 
Male:Female 
Mean age at Dx. 
of mets 
Response 
7 
4 : 3 
57.4 yrs. 
No Response 
3 
2:1 
54.0 yrs. 
3 
mm 
yrs. 
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Table 
Pt. 
13 
Age Race Sex 
F .A. 54 W F 
W.B. 40 w M 
P.B. 63 B F 
L.B. 45 W F 
J.C. 47 W M 
G.C. 19 W F 
M. C. 47 W F 
W. C. 33 w F 
J.C. 32 w F 
B.D. 27 w F 
F.F. 68 w M 
R.F. 43 w F 
C.G. 55 w M 
C. J. 59 w M 
J.K. 63 w M 
C.L. 50 w M 
D.L. 47 w M 
E.L. 69 w F 
H.L. 56 w M 
J.M. 55 w M 
M.N. 61 w M 
J.O. 60 w M 
D.P . 27 w M 
A. P. 63 w M 
G.S. 51 w F 
J.T. 67 w M 
R.T. 31 w M 
G.W. 50 w p 
J.Y. 46 w F 
H. Z . 50 w F 
Histology* Stage 
N,111,3.8 I 
SS,IV I 
IV 
SS IV I 
N+SS, IV I 
V I 
II 
SS, IV I 
III I 
I 
V I 
N I 
II 
V I 
SS, IV I 
SS, III I 
LMM II 
III I 
N, IV I 
LMM IV 
IV 
III II 
IV 
I 
N, V IV 
SS, II 
SS, II I 
I 
II 
Survival 
Site (mos.) 
back 6 
ear 13 
leg 17 
shoulder 3 
foot 3 + 
shoulder 9 
shoulder 13 + 
back 3 
back 4 
forehead 48 + 
58 
calf 11 
shoulder 17 + 
thumb 4 
toe 2 
back 5 
trunk 9 
forehead 6 
nose 24 + 
back 15+ 
shoulder, 
neck 
15 
knee 21 + 
scalp 10 
shoulder 5 
7+ 
flank 3 
scalp 9 
scapula 3 
hand 7 
back 11+ 
*Classification, Clark level, Breslow (mm.) 
N nodular melanoma 
SS superficial spreading melanoma 
LMM lentigo maligna melanoma 
+ "+" indicates patient alive at last follow-up. 
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Fig. i. Growth curve of hypothetical tumor on arithmetic coordinates. 
Number of Doublings 
Fig. 2. Growth curve of same hypothetical tumor on semilo-tarithmic scale. 

DAYS 
Fig. 3. Chart for estimating doubling time directly 
from measured diameter of nodules. This graph 
paper is based on the logarithm of the cube root. 
The heavy, evenly spaced lines represent succes¬ 
sive doublings in volume. The procedure is as 
follows: (a) The diameter of the pulmonary 
metastasis at the first observation is plotted on 0 
vertical axis. The diameter of the same nodule at 
the second observation is plotted on vertical line 
appropriate to the interval in days between the 
first and second observation; (b) draw straight 
line between plotted diameters; (c) where this line 
crosses any two heavy lines indicating doubling, 
drop two verticals to the base line; (d) the hori¬ 
zontal distance between these two vertical lines 
represents the doubling time in days. 
N
U
M
B
E
R
 
O
F
 
D
O
U
B
L
IN
G
S 

DAYS (KREBS) 
Fin. 4.—An arithmetic plot of (1) the theoretical Gompertz curve giving the best fit by the 
method of least squares to the experimental data. Krebs ascites carcinoma. The circles are the 
original experimental points. Data of Patt and Blackford (1954). (2) Growth curve of Esche- 
licitia coli. B r. grown in broth culture.* (3) An exponential curve fitted to the early growth 
date, showing the course growth would have taken if no retardation had occurred in either 
the bacterial culture or the tumor. The small scale of the graph obscures the fact that the early 
experimental points for the tumor also deviate from the exponential curve, as would be neces¬ 
sary to allow us to compute an upper limit of growth on the basis of a Gompertz function. 
* Data kindly ei\en us by H. Kubitsehek. of the Argonne National Laboratory. 
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